Inhibitors of Galectins and Implications for Structure-Based Design of Galectin-Specific Therapeutics

被引:22
|
作者
Blanchard, Helen [1 ]
Bum-Erdene, Khuchtumur [1 ]
Hugo, Matthew W. [1 ]
机构
[1] Griffith Univ, Inst Glyc, Gold Coast Campus, Qld 4222, Australia
关键词
MODIFIED CITRUS PECTIN; CYCLODEXTRIN-BASED GLYCOCLUSTERS; ARGININE-ARENE INTERACTIONS; PROSTATE-CANCER; MAMMALIAN GALECTINS; TETRAVALENT GLYCOCLUSTERS; INDUCED APOPTOSIS; CELL APOPTOSIS; MESSENGER-RNA; TUMOR-GROWTH;
D O I
10.1071/CH14362
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Galectins are a family of galactoside-specific lectins that are involved in a myriad of metabolic and disease processes. Due to roles in cancer and inflammatory and heart diseases, galectins are attractive targets for drug development. Over the last two decades, various strategies have been used to inhibit galectins, including polysaccharide-based therapeutics, multivalent display of saccharides, peptides, peptidomimetics, and saccharide-modifications. Primarily due to galectin carbohydrate binding sites having high sequence identities, the design and development of selective inhibitors targeting particular galectins, thereby addressing specific disease states, is challenging. Furthermore, the use of different inhibition assays by research groups has hindered systematic assessment of the relative selectivity and affinity of inhibitors. This review summarises the status of current inhibitors, strategies, and novel scaffolds that exploit subtle differences in galectin structures that, in conjunction with increasing available data on multiple galectins, is enabling the feasible design of effective and specific inhibitors of galectins.
引用
收藏
页码:1763 / 1779
页数:17
相关论文
共 50 条
  • [1] Structure-based design of protease inhibitors as therapeutics: Some examples.
    Reich, SH
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 219 : U595 - U595
  • [2] Structure-based design of inhibitors specific for bacterial thymidylate synthase
    Stout, TJ
    Tondi, D
    Rinaldi, M
    Barlocco, D
    Pecorari, P
    Santi, DV
    Kuntz, ID
    Stroud, RM
    Shoichet, BK
    Costi, MP
    BIOCHEMISTRY, 1999, 38 (05) : 1607 - 1617
  • [3] Rational, structure-based design of mRNA therapeutics
    Hall, Michelle
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 256
  • [4] Structure-based design of molecular cancer therapeutics
    van Montfort, Rob L. M.
    Workman, Paul
    TRENDS IN BIOTECHNOLOGY, 2009, 27 (05) : 315 - 328
  • [5] Towards the structure-based design of oligonucleotide therapeutics
    Egli, M
    ADVANCES IN ENZYME REGULATION, VOL 38, 1998, 38 : 181 - 203
  • [6] Structure-based design of thrombin inhibitors
    Pfau, R
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2003, 6 (04) : 437 - 450
  • [7] Structure-Based Design of Ricin Inhibitors
    Jasheway, Karl
    Pruet, Jeffrey
    Anslyn, Eric V.
    Robertus, Jon D.
    TOXINS, 2011, 3 (10): : 1233 - 1248
  • [8] Structure-based design of stromelysin inhibitors
    Dotouhi, N
    Joshi, P
    Visnick, M
    Tautz, W
    Hull, K
    Sheffron, A
    Pietranico, S
    Vermeulen, J
    Michoud, C
    Berthel, S
    Walsky, R
    Coffey, J
    Lugo, A
    Lusch, L
    Rowan, K
    Hanglow, A
    Orzechowski, L
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1996, 211 : 213 - MEDI
  • [9] Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors
    Ran, Xu
    Zhao, Yujun
    Liu, Liu
    Bai, Longchuan
    Yang, Chao-Yie
    Zhou, Bing
    Meagher, Jennifer L.
    Chinnaswamy, Krishnapriya
    Stuckey, Jeanne A.
    Wang, Shaomeng
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (12) : 4927 - 4939
  • [10] STRUCTURE-BASED DESIGN OF CHLOROMETHYL KETONE INHIBITORS SPECIFIC FOR THE SN SUBSITE OF GINGIPAINS
    Grembecka, J.
    Bialas, A.
    Mucha, A.
    JOURNAL OF PEPTIDE SCIENCE, 2004, 10 : 212 - 212